

This is a repository copy of *Transcriptional regulation of SPROUTY 2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3.*

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/106327/

Version: Accepted Version

Article:

Clarke, M., Volpe, G., Sheriff, L. et al. (6 more authors) (2017) Transcriptional regulation of SPROUTY 2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3. Leukemia, 31. pp. 957-966. ISSN 0887-6924

https://doi.org/10.1038/leu.2016.289

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



1	Transcriptional regulation of SPROUTY 2 by MYB
2	influences myeloid cell proliferation and stem cell
3	properties by enhancing responsiveness to IL-3
4	
5	Mary Clarke, Giacomo Volpe, Lozan Sheriff, David Walton, Carl Ward, Wenbin Wei,
6	Stephanie Dumon ¹ , Paloma García ¹ and Jon Frampton ^{1,2}
7	
8	Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences,
9	University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
10	
11	¹ Co-senior authors
12	² Corresponding author, Email j.frampton@bham.ac.uk
13	
14	Keywords: MYB / myeloproliferative neoplasm / hematopoietic stem cells / IL-3 signaling
15	Running title: MYB modulates myeloproliferation through IL-3 signaling
16	
17	Word count: 3988
18	

19 ABSTRACT

Myeloproliferative neoplasms (MPN), which overproduce blood cells in the bone marrow, 20 have recently been linked with a genetically determined decrease in expression of the MYB 21 22 transcription factor. Here, we use a mouse MYB knockdown model with an MPN-like 23 phenotype to show how lower levels of MYB lead to stem cell characteristics in myeloid 24 progenitors. The altered progenitor properties feature elevated cytokine responsiveness, 25 especially to IL-3, which results from increased receptor expression and increased MAPK activity leading to enhanced phosphorylation of a key regulator of protein synthesis, 26 ribosomal protein S6. MYB acts on MAPK signaling by directly regulating transcription of the 27 gene encoding the negative modulator SPRY2. This mechanistic insight points to pathways 28 that might be targeted therapeutically in MPN. 29

31 INTRODUCTION

Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematological disorders 32 characterized by over production of one or more myeloid lineages that can lead to the 33 evolution of myeloid leukemia. Several genetic lesions have been described that lead to the 34 evolution of MPN, exemplified by JAK2^{V617F} and mutations in calreticulin (CALR) and the 35 thrombopoietin receptor, MPL (1-3). Although the JAK2^{V617F} mutation is associated with 36 37 more than 95% of polycythemia vera (PV) and 50-60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) there are increasing reports of JAK2^{V617F}-negative MPN 38 39 and indeed cases of MPN that are negative for mutations in JAK, MPL and CALR. Recently, 40 a study on MPN patients identified potential mutations that predispose to and drive the development of MPN (4). One of the polymorphisms identified was rs9376092, which is 41 found 75 kb telomeric of the gene encoding the oncogenic transcription factor MYB. 42 Interestingly, this risk allele is associated with reduced MYB RNA expression in both normal 43 myeloid cells and JAK2^{V617F} mutant BFU-E from ET patients compared to the equivalent wild 44 type cells. 45

Studies on mouse models have suggested that decreased activity of MYB can lead to phenotypes that reflect at least some aspects of MPN (5, 6). We showed that reduced levels of MYB in mice homozygous for a knockdown allele ($MYB^{KD/KD}$) result in a MPN-like disorder resembling human ET, which is underpinned by a KIT⁺CD11b⁺Lin^{low} (K11bL) cell that is stem cell like (5).

In this study we have sought to understand how a lower level of MYB in myeloid progenitors leads to a gain of stem cell characteristics and the MPN-like phenotype, and thereby shed light on the observed effect of lower MYB levels on the development of human MPN. We further characterize $MYB^{KD/KD}$ K11bL cells and show that enhanced IL-3 signaling is a key consequence of lower MYB activity. The enhanced response to IL-3 is primarily the result of an increase in MAPK signalling. We demonstrate that these changes arise at least in part 57 from reduced activity of the signaling modulator SPROUTY2, the gene expression of which

- 58 is directly regulated by MYB.
- 59

60 MATERIALS AND METHODS

61 Sources of haematological tissues

Animal experiments were carried out in accordance with UK legislation. Human umbilical
 cord blood samples were collected with informed written consent and was approved by the
 NRES Committee North West – Haydock.

65 Flow cytometry and cell sorting

This was performed as previously described (7). All mouse antibodies are listed in
Supplementary Table 1. For human CD34+ cell sorting, we used anti-CD34 PE (BD
Biosciences).

69 Phospho-flow analysis

K11bL cells were cultured in serum-free medium for 90 min, and then stimulated with
20ng/ml IL-3 for 15 min at 37°C. Phospho-flow was performed as previously described (8).
Antibodies were PE-conjugated (Cell Signalling Technology). For inhibition experiments,
cells were pre-treated with either 1µM Rapamycin or 10µM U0126 (Sigma) in serum-free
media at 37°C for 1 hour.

75 Engraftment potential of stem cells

Cell transplantation experiments were carried as previously described (5) with 10 000 K11bL
 (CD45.2/CD45.2) cells injected together with 3x10⁵ reference (CD45.1/CD45.2) bone
 marrow cells.

79 Homing assays

Sorted K11bL cells were labeled with 0.3 mg/ml Xenolight DiR (Caliper Life Sciences) for 30
 min at 37°C. Cells were washed and re-suspended in 150µl of PBS, and injected via the tail

vein into lethally irradiate hosts (B6:SJL). Details of IVIS imaging conditions can be found in
 Supplementary Information.

84 Transfection and cell culture

Human CD34⁺ were sorted and transfected using the 4D-Nucleofector system (Lonza) with FAM-labeled siRNAs (**Supplementary Table 2**). Following transfection, CD34⁺ cells were cultured for 24 hours in RPMI supplemented with 10% FBS, 50ng/ml SCF, 10ng/ml IL3 and 20ng/ml IL6. After 24 hours cells were plated in complete methylcellulose (Methocult GF H84435). Colony morphology and number were assessed between 7-14 days.

90 Transduction of bone marrow cells

Lentiviruses (Origene) expressing shRNA *SPRY2* (TG515588) or *II3ra* (TG516353) or *SPRY2* ORF together with GFP, were generated as described (9). Bone marrow or K11bL cells were cultured in the presence of 3µg/ml Polybrene (Sigma) with lentivirus at an MOI of 10. Cells were cultured for 4 hours, washed and either injected into lethally irradiated mice or further cultured for 20 hours. Infection efficiency was assessed based on GFP expression.

96 Gene expression analysis

Affymetrix Mouse Gene 1.0 ST array analysis was performed on K11bL cells. The GEO
accession number for the data deposited is GSE74140. Further detail can be found in
Supplementary Information. Quantitative PCR was performed as previously described (5).
TaqMan PCR primers (Applied Biosystems) and primer sequences are listed in
Supplementary Table 3.

102 X-ChIP analysis

X-ChIP assays were performed as previously described (10) using antibodies from Santa
 Cruz Biotechnology and anti-MYB antibody from Merck Millipore. Primers for detection of
 MYB binding to the *SPRY2* and *DUSP6* genes are listed in **Supplementary Table 4**.

106 Statistical analysis

Significance of data sets was assessed using two-tailed unpaired Student's t-test with
 significance set at p<0.05.

109

110 **RESULTS**

111 MYB^{KD/KD} K11bL cells exhibit myeloid bias and have stem cell characteristics

When K11bL cells, which are more abundant in MYB^{KD/KD} mice compared to MYB^{WT/WT} 112 controls (Figure 1A), were transplanted into lethally irradiated mice they engrafted 113 significantly, irrespective of whether they were $MYB^{WT/WT}$ or $MYB^{KD/KD}$ (Supplementary 114 Figure 1A). However, engrafted MYB^{KD/KD} K11bL cells gave rise predominantly in the 115 peripheral blood to CD11b⁺ myelomonocytic cells whereas *MYB^{WT,WT}* K11bL cells largely 116 117 differentiated into B220⁺ B-lymphoid cells (Figure 1B), and all bone marrow K11bL cells derived from *MYB^{KD/KD}* donor cells were positive for CD41 (Supplementary Figure 1B). 118 Importantly, when bone marrow isolated from the primary recipients was transplanted into 119 secondary hosts, MYB^{WT/WT} K11bL cells failed to support serial engraftment, whereas 120 *MYB^{KD/KD}* cells were able to perpetuate the myeloproliferative phenotype (**Supplementary** 121 122 Figure 1C).

We confirmed the MYB^{KD/KD} lineage bias of K11bL cells by in vitro colony assay. MYB^{KD/KD} 123 cells predominantly formed CFU-M and CFU-M/Mk colonies, failing to produce colonies of 124 granulocytic or erythroid morphology, whereas *MYB^{WT/WT}* K11bL cells were able to undergo 125 a full program of myeloid differentiation (Supplementary Figure 1D). Microarray analysis 126 of K11bL cells confirmed the shift from a lymphoid to a myeloid bias, Gene Ontogeny (GO) 127 analysis showing that compared to MYB^{WT/WT} K11bL cells, MYB^{KD/KD} cells exhibit higher 128 expression of genes associated with myeloid differentiation, and reduced levels of lymphoid-129 associated genes (Supplementary Table 5). 130

We sought to identify the differences in surface marker and gene expression that might explain the stem cell-like transplantation behaviour of $MYB^{KD/KD}$ K11bL cells (**Figure 1Ci and**

Supplementary Figure 1E). MYB^{KD/KD} K11bL cells have higher levels of expression of the 133 integrins CD51 (α_V), CD41 (α IIb) and CD61 (β 3) and the adhesion molecule CD62 (P-134 selectin). Since MYB^{KD/KD} K11bL cells have gained stem cell properties, we analysed the 135 136 microarray for expression of homing and bone marrow retention molecules together with flow cytometric analysis of some of the key proteins. Analysis of RNA expression data for the 137 GO group "cell chemotaxis" (GO:0060326) revealed an increase in expression of genes 138 associated with homing and invasion of extramedullary sites of hematopoiesis (eg Ccr1) and 139 140 lower levels of genes regulating bone marrow retention (eg Vcam1) (Supplementary Table 6). Flow cytometric analysis confirmed the reduction of VCAM1 on the surface of MYB^{KD/KD} 141 K11bL cells (Figure 1Cii and Supplementary Figure 1E). Consistent with their stem cell 142 characteristics, MYB^{KD/KD} K11bL cells have higher levels of SCA1 and CD34, and exhibit a 143 144 small but significantly higher level of the SLAM marker CD150 (p≤0.01) (Figure 1Ciii and 145 Supplementary Figure 1E).

146 MYB^{KD/KD} K11bL cells have an enhanced response to IL-3

Interestingly, analysis of genes in the GO group "cytokine-mediated signaling pathway" 147 (GO:0019221) revealed that a number of cytokine receptor genes are more highly expressed 148 in MYB^{KD/KD} K11bL cells compared to the MYB^{WT/WT} equivalent. Amongst these genes we 149 identified CSF2RB (IL3RBC) as being more highly expressed in MYBKD/KD K11bL cells (2.25-150 fold p=7x10⁻⁵ Supplementary Table 7). This difference, together with that of the other IL-3 151 receptor component IL3RA, was confirmed by quantitative PCR (Figure 2A). 152 Correspondingly, immunofluorescence analysis showed that the expression of IL3RA 153 (CD123) and CSF2RB (CD131) are greater on MYB^{KD/KD} K11bL cells than the MYB^{WT/WT} 154 equivalents (Supplementary Figure 2A). 155

156 It is well documented that malignant cells can exhibit a heightened response to growth 157 factors, augmenting their proliferation and survival. Our observations on altered IL-3 receptor 158 expression on $MYB^{KD/KD}$ K11bL cells combined with the fate of the cells following 159 transplantation led us to ask if altered responses to IL-3 could be dictating stem cell

characteristics. When we plated cells in semi-solid media containing a range of 160 concentrations of IL-3, this revealed that MYB^{KD/KD} K11bL cells have a heightened response 161 162 to the cytokine as manifested by higher colony numbers. This enhancement was significant 163 at all concentrations tested down to 0.02ng/ml (p≤0.05) (Figure 2B). Analysis of colony morphology showed that MYB^{WT/WT} K11bL cells yielded colonies containing granulocytes 164 (CFU-G), macrophage (CFU-M), and a mix of both of these cell types (CFU-GM). In 165 contrast, MYB^{KD/KD} cells formed mainly CFU-M, which were highly proliferative and gave rise 166 to disperse colonies as well as a few colonies containing both macrophages and 167 megakaryocytes (Figure 2C). 168

169 IL-3 signaling is critical for *MYB^{KD/KD}* K11bL cell function

To determine how dependent $MYB^{WT/WT}$ and $MYB^{KD/KD}$ K11bL cells are on signaling through the IL-3 receptor, even in the presence of other growth factors, we used a neutralizing antibody against the IL-3 receptor subunit IL3RB to inhibit the response to IL-3. We observed a marked reduction in colony number from 19±1 to 8±0 (p=0.004) for $MYB^{KD/KD}$ K11bL cells, but saw no effect on $MYB^{WT/WT}$ cells (**Figure 3A**), suggesting that $MYB^{KD/KD}$ K11bL cells are critically dependent on signaling through the IL-3 receptor.

176 Since IL3RB is common to signaling through both the IL-3 and GM-CSF receptors, we 177 wanted directly to assess the effect of knocking down the other IL-3-specific subunit, IL3RA. MYB^{KD/KD} K11bL cells were transduced with lentivirus expressing IL3RA shRNA and were 178 179 then transplanted into lethally irradiated mice. Co-expression of GFP from the shRNA vector 180 indicated that we achieved a transduction rate of ~70% (Figure 3Bi). Engraftment was apparent after one month, however the proportion of donor cells in the peripheral blood was 181 markedly reduced when IL3RA was knocked down. By 3 months this difference was more 182 evident (Figure 3Bii). Interestingly, MYB^{KD/KD} donor cells expressing shRNA IL3RA had a 183 significantly reduced differentiation towards monocytes (Gr1⁻CD11b⁺) compared to control 184 185 cells (69±3% compared to 57±2%, p≤0.01) and a corresponding increase in differentiation towards granulocytes (Gr1⁺CD11b⁺) (Supplementary Figure 2B). Similar to previous 186

observations, the ratio of shRNA control transduced donor $MYB^{KD/KD}$ cells rapidly increased between 1 and 7 months following transplantation, whereas the cells expressing shRNA *IL3RA* were maintained at their low engraftment ratio, indicating a necessity for the expression of IL3RA for engraftment of $MYB^{KD/KD}$ K11bL cells (**Supplementary Figure 2C**).

191 The influence of enhanced IL-3 signaling on engraftment was further examined with respect 192 to short term migration and homing following transplantation. Following injection of fluorescently labeled K11bL cells it was evident after one hour that the MYBKD/KD cells have 193 distinct homing behavior compared to MYB^{WT,WT} K11bL cells, with the predominant signal 194 195 emanating from the spleen. Using the IL3RB blocking antibody we then showed that active signaling through IL3RB is required for the ability of *MYB^{KD/KD}* K11bL cells to home towards 196 the spleen as evidenced by a loss of fluorescence signal (9 ± 1 to 0.44 ± 0.2 photon/s p=0.007) 197 when IL3RB was blocked (Figure 3C and Supplementary Figure 2D). 198

199 Signaling downstream of the IL-3 receptor is enhanced in *MYB^{KD/KD}* K11bL cells

We used phospho-flow cytometry to determine if the enhanced response of $MYB^{KD/KD}$ K11bL cells is reflected in the phosphorylation status of molecules that could influence the interpretation of IL-3-mediated signaling. The only significant difference in steady-state phosphorylation was observed in rpS6^{Ser235/236} and STAT5^{Tyr694}, the former exhibiting a median fluorescence intensity (MFI) of 18.9±1.1 in $MYB^{WT/WT}$ K11bL cells versus 52.5±2.4 (p=0.003) in $MYB^{KD/KD}$ cells and the latter being 26.4±1.5 in $MYB^{WT/WT}$ compared to 47.9±0.3 (p=0.0026) in $MYB^{KD/KD}$ cells (**Supplementary Figure 3A**).

In order to assess the effect of IL-3 stimulation on the dynamics of phosphorylation, K11bL cells were starved of serum prior to stimulation with IL-3 and subsequent analysis 15 min later. We observed differences in both the extent of the response and the relative degree of phosphorylation of rpS6^{Ser235/236} and rpS6^{Ser240/244}. Hence, stimulation of K11bL cells with IL-3 led to an increase in rpS6^{Ser235/236} phosphorylation, reflected in a MFI shift of 105±36 to 232±32 (p=0.009) for *MYB^{WT/WT}* and 91±29 to 480±82 (p=0.0002) for *MYB^{KD/KD}* (**Figure 4Ai and Supplementary Figure 3B**). This also revealed that *MYB^{KD/KD}* K11bL cells showed a significantly greater increase in the proportion of cells phosphorylated at this site and reached an overall higher level of phosphorylation, the MFI being twice as great as that seen in $MYB^{WT/WT}$ K11bL cells (p=0.0063; **Supplementary Figure 3B**). We therefore also checked for changes in phosphorylation at the rpS6^{Ser240/244} site. Following IL-3 stimulation, no significant increase in phosphorylation was seen in $MYB^{WT/WT}$ K11bL cells, whereas $MYB^{KD/KD}$ K11bL cells demonstrated a small increase, seen as a shift in MFI of 13.3±3 to 22.9±4 (p=0.02) (**Figure 4Ai and Supplementary Figure 3C**).

Phosphorylation of rpS6^{Ser235/236} can occur through activation of the PI3k/AKT/mTOR or 221 RAS/MAPK pathways, whereas only the former leads to the modification of rpS6^{Ser240/244} 222 (11). We examined the phosphorylation status of AKT (Thr308 and Ser473) and p44/42 223 MAPK (ERK1/2) to investigate the relative use of the two pathways. At 15 min post IL-3 224 225 stimulation we failed to detect any phosphorylation of AKT or p44/42 MAPK (data not shown). However, reasoning that the response to IL-3 might be very rapid, we also looked at 226 227 phosphorylation at 5 min following IL-3 addition. A significant increase in phosphorylation of AKT^{Thr308} was seen as a shift in MFI from 6.7±1.5 to 13.8±4.5 (p=0.047) (Figure 4Aii and 228 229 Supplementary Figure 3D). We also observed an increase in the percentage of cells positive for p44/42 MAPK phosphorylation from 4±3% to 23±5% (p=0.04) in MYBKD/KD K11bL 230 cells but not in the *MYB^{WT/WT}* equivalent (Figure Aii and Supplementary Figure 3E). 231

232 To confirm the dependence of rpS6 phosphorylation on the PI3k/AKT/mTOR and RAS/MAPK pathways and better to define how the specificity and balance of activity differs 233 in MYB^{KD/KD} K11bL cells compared to MYB^{WT/WT} cells, we performed IL-3 stimulations 234 following pre-treatment of the K11bL cells with inhibitors of mTOR (Rapamycin) or MEK 235 (U0126). Treatment of MYB^{WT/WT} cells with Rapamycin but not U0126 resulted in a loss of 236 phosphorylation of rpS6^{Ser235/236} from 21.8±3.2% to 12.5±2.7% (p=0.02, Supplementary 237 Figure 3F). Similar analysis of rpS6 in *MYB^{KD/KD}*K11bL cells showed that phosphorylation at 238 Ser235/236 was inhibited by U0126 (45.5±7.1% to 13.7±3.5%; p=9.5x10⁻⁰⁵) but not by 239 Rapamycin, whereas the Ser240/244 site modification was susceptible to inhibition of mTOR 240

but not MEK (**Figure 4B and Supplementary Figure 3F**). This implies that one aspect of the distinctive cytokine responsiveness seen in $MYB^{KD/KD}$ K11bL cells relates to a shift in the relative usage of the signaling pathways downstream of the IL-3 receptor.

The baseline phosphorylation of $STAT5^{Tyr694}$ was lower in $MYB^{KD/KD}$ K11bL cells but upon stimulation with IL-3 increased to a level similar to that seen in $MYB^{WT/WT}$ cells following their treatment with cytokine (**Figure 4Ci**). Consistent with the phosphorylation of STAT5 being elicited through a JAK protein, we observed no effect on the level of phosphorylation in the presence of the mTOR or MEK inhibitors (**Figure 4Cii**).

249 The expression of signaling-associated genes defines the *MYB^{KD/KD}* K11bL phenotype

Based on the phosphorylation results, we further analysed the array data to look at GO 250 251 groups associated with signaling. Analysis of deregulated genes involved in intracellular signal transduction (GO:1902532) (Supplementary Table 8) and in particular proteins 252 involved in the ERK signalling cascade (GO:0070372) (Supplementary Table 9) highlighted 253 the altered expression of several genes. In particular, we noted that MYB^{KD/KD} K11bL cells 254 exhibit lower expression of the genes encoding the inhibitor SPROUTY2 (SPRY2), the dual 255 specificity phosphatase 6 (DUSP6), and the RAS protein activator (RASA2), and higher 256 expression of dual specificity phosphatase 3 (DUSP3), and suppressor of cytokine signalling 257 258 3 (SOCS3).

In order to confirm which of these differences might reflect direct regulation by MYB we used 259 our conditional MYB knockout (12). K11bL cells were isolated from control mice 260 (MYB^{+/+}:Cre) and MYB knockout (MYB^{F/F}:Cre) mice 24 hours after induction of deletion, and 261 the levels of RNA for MYB and the selected genes were measured by quantitative RT-PCR. 262 263 This confirmed that SPRY2 and DUSP6 RNA levels were depleted, whilst the levels of IL3RA, CSF2RB, CSFR2RB2, CSFR1, SOCS3, DUSP3, MECOM, and CCND1 were higher, 264 265 suggesting that the expression of these genes could be directly inhibited by MYB (Figure 5A). 266

267 MYB directly regulates expression of the SPRY2 and DUSP6 genes

We next used X-ChIP to determine if positive regulation of the SPRY2 and DUSP6 genes by 268 269 MYB correlates with binding of the protein to gene regulatory regions. We prepared chromatin from the murine HSC line HPC-7 (13), and used an antibody against MYB for 270 immunoprecipitation of SPRY2 and DUSP6 gene fragments corresponding to in vivo binding 271 sites for the factor. Primers for quantitative PCR were designed around highly conserved 272 273 regions that contained potential MYB binding sequences. In this way, we demonstrated MYB 274 binding to the SPRY2 promoter (-0.55kb from ATG, Figure 5B) and the DUSP6 promoter (-275 2.7kb from ATG, Figure 5C), whereas there was no significant enrichment of either the SPRY2 enhancer (-26kb from ATG) or the DUSP6 distal promoter (-2.7kb from ATG) 276 (Supplementary Figure 4). 277

Reduced MYB expression in human progenitors mirrors the changes seen in *MYB^{KD/KD}* K11bL cells

280 To examine if our observations in the mouse system are paralleled in human cells we transfected CD34+ cord blood cells with MYB siRNA. This achieved a 50% reduction in 281 282 MYB gene expression at 24 hours, and upon plating cells in methylcellulose containing 283 myeloid growth factors we observed that knockdown of MYB leads to an increase in CFU-M 284 and CFU-Mk and a reduction in CFU-G, CFU-GEMM and BFU-E, in line with the broad phenotypic changes seen in MYBKD/KD K11bL cells (Figure 6A). We also showed that the 285 286 knockdown of MYB in the human cells led to a significant decrease in the expression of SPRY2 and increased expression of IL3RA and CSF1R, exactly as we saw in murine 287 MYB^{KD/KD} K11bL cells, however, unlike in mouse K11bL cells, the expression of DUSP6 was 288 289 significantly increased (Figure 6B).

290 Manipulation of *SPRY2* expression in *MYB*^{*WT/WT*} cells partially recapitulates the 291 $MYB^{KD/KD}$ stem cell phenotype 292 Based on the apparent importance of enhanced IL-3-dependent RAS/MAPK signaling in MYB^{KD/KD} K11bL cells and the conserved MYB-dependent expression of SPRY2 in both 293 294 mouse and human progenitor cells, we reasoned that SPRY2 is pivotal to the way in which 295 IL-3 can influence stem cell characteristics of myeloid progenitors. In order to assess the degree to which SPRY2 is responsible for the gain of stem cell function, we transduced 296 MYB^{WT/WT} K11bL cells with a lentiviral vector expressing shRNA directed against SPRY2 and 297 assayed their ability to form hematopoietic colonies in vitro. MYBWT/WT K11bL cells 298 transduced with control virus demonstrated normal colony formation in complete 299 methylcellulose. In contrast, MYB^{WT/WT} cells transduced with lentivirus expressing SPRY2 300 301 shRNA (which exhibited >95% knockdown - Supplementary Figure 5A) demonstrated reduced CFU-G colonies and increased CFU-M colonies, similar to the situation seen for 302 MYB^{KD/KD}K11bL cells (Figure 7A). Secondary plating of MYB^{WT/WT}K11bL cells experiencing 303 304 SPRY2 knockdown resulted in colonies that covered the plate, whereas control cells formed 305 very small, sparsely distributed colonies (Supplementary Figure 5B). These SPRY2 knockdown MYB^{WT/WT} K11bL secondary colonies showed increased levels of KIT and CD34 306 compared to the control cells (Supplementary Figure 5C). 307

Transplantation assays of MYB^{WT/WT} K11bL cells transduced with control or SPRY2 shRNA 308 revealed a higher donor to reference ratio when levels of SPRY2 were reduced (Figure 7B). 309 310 This enhanced engraftment was further amplified by 3 months but the contribution to 311 peripheral myeloid cells (CD11b+) was not altered (Supplementary Figure 5D). Secondary 312 transplantation revealed the acquisition of long-term repopulating ability by the SPRY2 313 knockdown K11bL cells (Supplementary Figure 5E). We then asked if over expression of SPRY2 in MYBKD/KD K11bL cells could reverse their proliferation and differentiation 314 characteristics. Colony forming assays of MYBKD/KD K11bL cells transduced with a lentivirus 315 expressing SPRY2 resulted in a significant reduction in colony number in complete 316 methylcellulose (Figure 7C). Additionally the SPRY2-overexpressing MYB^{KD/KD} K11bL cells 317

gave rise to a lower proportion of megakaryocyte colonies and increased granulocytic
colonies compared to K11bL cells infected with control virus (Figure 7C).

320

321 DISCUSSION

322 MYB was originally shown to be a critical regulator of hematopoiesis since complete ablation 323 abolished definitive hematopoiesis (14). The role that MYB plays in adult hematopoiesis has been studied using mouse models with reduced activity of the protein (5, 6, 12, 15), 324 revealing a role for MYB in immature proliferating hematopoietic cells. Here we have sought 325 to link recent observations on the genetic predisposition to MPN caused by lower levels of 326 expression of MYB (4) with the phenotype seen in our mouse model for decreased MYB 327 328 activity. We show that lower MYB levels in myeloid progenitors results in; (i) altered short-329 term homing towards the spleen, (ii) differentiation towards myelomonocytic cells, and (iii) a stem cell phenotype, including self-renewal potential that is not seen in the normal 330 331 equivalents and giving a phenotype more similar to those described in some chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL) stem cells (16, 17). 332

Key to the *MYB^{KD/KD}* phenotype is altered IL-3 signaling, particularly along the RAS/MAPK pathway. Our results suggest that enhanced IL-3 signaling is responsible for aspects of the aberrant stem cell phenotype, including homing to the spleen, engraftment potential, and lineage bias. Such acquired properties likely have relevance to the leukemia stem cellspecific role of IL-3 receptor in acute myeloid leukemia (AML), which has been shown to be an effective target for an anti-IL3RA (CD123) antibody (18).

We are presently investigating the mechanisms by which increased IL-3-dependent signaling leads to the *MYB*^{KD/KD} phenotype. The RAS/MAPK pathway appears to be central and, although the nature of the critical targets remains unclear, we found evidence for the activation of ribosomal protein S6, which itself plays an essential role in protein translation of several pro-survival protein genes such as MYC, BCL-XL, and SURVIVIN, and might therefore contribute to the gain of stem cell properties. Interestingly, there are descriptions of the importance of ERK/MAPK in self-renewal of both embryonic and adult stem cells (19, 20). The RAS/MAPK pathway is frequently activated in hematological malignancy and has been implicated in the sensitivity and resistance of cells to therapy (21), including in other MPN models such as the KRAS mutant mouse (22).

349 We explored the mechanisms by which reduced MYB activity leads to enhanced IL-3 350 signaling, and found that these involved multiple direct and indirect targets, and including 351 both positively and negatively regulated genes. Aside from what appears to be coordinated 352 positive regulation of several cytokine receptor genes, MYB also normally seems to provide 353 a coordinated controlling influence on RAS/MAPK signaling by promoting the expression of negative pathway regulators, including SPRY2 and DUSP6. SPRY2, which prevents the 354 interaction between RAS and GRB2-SOS (23) following their recruitment by SHC when it 355 associates with the IL-3 receptor, seems to be relevant in both the mouse and human 356 systems we examined. The lower expression of SPRY2 would be expected to release the 357 inhibition of RAS, leading to an increased sensitivity to IL-3. Interestingly, knockdown of 358 359 SPRY2 in wild type progenitor cells both shifted their phenotype and enhanced engraftment potential, partially reflecting the overall phenotype of the MYB^{KD/KD} cells. 360

We postulate a working model for the signaling pathways utilized in K11bL cells in both 361 MYB^{WT/WT} and MYB^{KD/KD} mice (Figure 8), and clearly our study has opened up a whole new 362 363 chapter in the understanding of the pivotal role of MYB in both normal and malignant hematopoiesis. Although numerous additional mechanisms undoubtedly combine to give rise 364 to the complete MYB^{KD/KD} MPN-like phenotype, our findings suggest that IL-3-dependent 365 366 signaling plays a major role, affecting the regulation of genes responsible for migration, proliferation, and differentiation. For those hematological disorders where MYB activity is 367 368 affected, including MPN, the knowledge that signaling downstream of IL-3 receptor is 369 affected as a direct result of altered MYB levels could open up the possibility for a more 370 direct approach to treatment.

371

372 ACKNOWLEDGMENTS

373 This work was supported entirely by Bloodwise.

374

375 CONFLICTS OF INTEREST

- 376 The authors declare no conflicts of interest.
- 377 Supplementary information is available at http://www.nature.com/leu/index.html

378

380 **REFERENCES**

381 1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-382 66. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic 383 2. 384 mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-90. 385 Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations 3. 386 in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 387 2006;108(10):3472-6. 388 4. Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, et al. Genetic variation at 389 MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 390 2015;6:6691. 391 5. Garcia P, Clarke M, Vegiopoulos A, Berlanga O, Camelo A, Lorvellec M, et al. Reduced c-Myb 392 activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis. EMBO J. 393 2009;28(10):1492-504. Lieu YK, Reddy EP. Conditional c-myb knockout in adult hematopoietic stem cells leads to 394 6. 395 loss of self-renewal due to impaired proliferation and accelerated differentiation. Proc Natl Acad Sci 396 U S A. 2009;106(51):21689-94. 397 7. Clarke M, Dumon S, Ward C, Jager R, Freeman S, Dawood B, et al. MYBL2 haploinsufficiency 398 increases susceptibility to age-related haematopoietic neoplasia. Leukemia. 2013;27(3):661-70. 399 Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: 8. 400 monitoring single cell signaling events. Cytometry A. 2003;55(2):61-70. 401 9. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced 402 pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells. 403 2009;27(3):543-9. 404 10. Dumon S, Walton DS, Volpe G, Wilson N, Dasse E, Del Pozzo W, et al. Itga2b regulation at the 405 onset of definitive hematopoiesis and commitment to differentiation. PLoS One. 2012;7(8):e43300. 406 Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, et al. RAS/ERK signaling 11. 407 promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent 408 translation. J Biol Chem. 2007;282(19):14056-64. Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J. Progression 409 12. 410 through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J. 411 2003;22(17):4478-88. 412 Pinto do OP, Kolterud A, Carlsson L. Expression of the LIM-homeobox gene LH2 generates 13. 413 immortalized steel factor-dependent multipotent hematopoietic precursors. EMBO J. 414 1998;17(19):5744-56. 415 Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, et al. A functional c-14. 416 myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65(4):677-89. 417 15. Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB, et al. c-Myb 418 and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005;8(2):153-419 66. 420 Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A, et al. Identification 16. 421 of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. 422 Blood. 2009;114(27):5415-25. Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, et al. The hematopoietic stem 423 17. 424 cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid 425 progenitor cells and reflecting loss of quiescence. Leukemia. 2009;23(5):892-9.

426 18. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody427 mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic
428 stem cells. Cell Stem Cell. 2009;5(1):31-42.

429 19. Chen H, Guo R, Zhang Q, Guo H, Yang M, Wu Z, et al. Erk signaling is indispensable for
430 genomic stability and self-renewal of mouse embryonic stem cells. Proc Natl Acad Sci U S A.
431 2015;112(44):E5936-43.

432 20. Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc
433 Biol. 2009;86(2):237-50.

434 21. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 435 2003;3(6):459-65.

436 22. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, et al. A MEK
437 inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med.
438 2011;3(76):76ra27.

Yusoff P, Lao DH, Ong SH, Wong ES, Lim J, Lo TL, et al. Sprouty2 inhibits the Ras/MAP kinase
pathway by inhibiting the activation of Raf. J Biol Chem. 2002;277(5):3195-201.

441 24. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for
442 high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185443 93.

444 25. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix
445 GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.

446 26. Smyth GK. Linear models and empirical bayes methods for assessing differential expression
447 in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.

449 SUPPLEMENTARY METHODS

450 Bone marrow cell isolation and culture

All mice were maintained on a C57/BL6 background and sacrificed at 4 weeks of age as a source of bone marrow. Conditional deletion of *MYB* was induced by intraperitoneal injection of 250µg poly(inosinic-cytidylic) acid (plpC, Sigma) and 24 hours later were sacrificed for bone marrow analysis. Peripheral blood was collected from the tail vein into acid citrate dextrose (ACD) solution. Sorted mouse K11bL cells were plated in complete methylcellulose medium (Methocult M3434, Stem Cell Technologies) containing TPO (25ng/ml). Methocult lacking growth factors (M3234) was used to assess the response to specific cytokines.

458 Homing assays

For live animal imaging, mice were shaved and imaged using an IVIS spectrum under 2.5% iso-fluorane (Caliper Life Sciences). Mice were imaged ventrally at 1 and 24 hours. Images were acquired by trans-illumination at 745nm excitation and 800nm emission with exposure times ranging from 1.4 seconds to 60 seconds, medium binning and f-stop 2. IVIS data was analysed using Living Image 4.0 software (Caliper Life Sciences).

464 Gene expression analysis

Scanned images of microarrays were analyzed using the Affymetrix GeneChip Command Console. Probe level quantile normalization (24) and robust multi-array analysis (25) on the raw CEL files were performed using Affymetrix Expression Console. Differentially expressed genes were identified using limma with absolute fold change >1.5 and p<0.01 (26). Gene ontogeny was analysed using Gene Ontology Enrichment Analysis Software Toolkit (GOEAST).

472 FIGURE LEGENDS

Figure 1 A) Whole bone marrow cells were gated for expression of KIT and CD11b and then analysed for expression of lineage markers **** $p \le 0.0001$. B) Primary donor-derived cells in the peripheral blood analyzed for expression of myeloid, B-cell, and T-cell markers at 3 months post-transplantation. Numbers represent average percentage of total cells. C) Representative (N=10) flow cytometry profiles of *MYB*^{WT/WT} (black) and *MYB*^{KD/KD} (red) K11bL cells (isotype control - solid grey).

Figure 2 A) Quantitative RT-PCR analysis of RNA expression for the indicated genes in
K11bL cells (N=3). B) 500 sorted K11bL cells from *MYB^{WT,WT}* and *MYB^{KD/KD}* mice were
plated in methylcellulose with varying concentrations of IL3. Colony number was scored after
7 days (N=2). C) Colony morphology of K11bL cells plated in M3234 containing 20ng/ml IL3. Inset: i) Representative images of *MYB^{WT,WT}* CFU-G (left), CFU-GM (middle), and CFU-M
(right) colonies, and ii) *MYB^{KD/KD}* CFU-M colonies

485 Figure 3 A) Sorted K11bL cells were incubated in the presence of 30µg/ml of isotype or anti-IL3RB neutralizing antibody prior to plating in complete methylcellulose. Colony number was 486 assayed after 7 days (**p≤0.01 N=3). B) MYBKD/KD K11bL cells were transduced with 487 488 lentivirus carrying shRNA control or shRNA *II3ra* before being injected into lethally irradiated 489 mice: i) Transduced cells remaining in culture were assessed for transduction efficiency by 490 GFP expression; ii) Peripheral blood from recipient mice was analyzed at 1 and 3 months 491 post-transplantation to assess engraftment, the gates showing the CD45.2+ donor cells with 492 the respective average reference:donor ratios. C) Staining with DiR and injection into lethally irradiated B6:SJL recipient mice. Recipients were imaged by IVIS after 24 hours by trans-493 illumination. The oval region highlighted indicates the region of the spleen measured. 494 Images are representative of N=4. 495

Figure 4. Representative plots depicting phospho-flow analysis of K11bL cells, and the response to IL-3 stimulation. A) K11bL cells were serum-starved (solid black/red) prior to stimulation with 20ng/ml IL-3 (dashed black/red) for 15 min and then fixed and permeabilzed before staining with antibodies against i) phospho-rpS6^{Ser235/236} and phosphor-rpS6^{Ser240/244} (N=9). And ii) phospho-AKT^{Thr308}, phospho-AKT^{Ser473} and phospho-p44/42 MAPK following IL-3 stimulation (N=3). (isotype control – pale grey) B) *MYB^{KD/KD}* K11bL cells were incubated with IL-3 in the presence and absence of mTOR inhibitor Rapamycin (1 μ M, red) or the MEK inhibitor U0126 (10 μ M, blue) (N=3). C) Staining of K11bL cells for P-Stat5^{Y694} following i) serum starvation (solid black/red) and stimulation with II3 (dashed black/red) and ii) following stimulation with IL3 in the presence of either Rapamycin (red) or U0126 (blue).


Figure 5 A) K11bL cells from MYB⁺⁺:Cre and MYB^{FF}:Cre bone marrow were sorted 24 hours 506 507 following intraperitoneal injection of plpC to induce Mvb gene deletion. Expression of the 508 indicated signaling-associated genes was analyzed by quantitative RT-PCR and normalized 509 against $\beta 2M$. Error bars represent SEM (N=3). B) Alignment of mammalian sequences for 510 the SPRY2 gene, showing the gene exonic structures, the presence of CpG islands, the 511 overall degree of sequence conservation, and the detail of the sequence conservation 512 around potential MYB binding sites (red box) that were spanned by the Q-PCR primers. The 513 histogram shows the results of quantitative PCR performed on HPC7 ChIP samples pulled 514 down by MYB antibody and analysed for enrichment of binding on sequences for SPRY2. The histogram illustrates the relative enrichment as determined by Q-PCR (N=3, 515 ***p≤0.001). C) A similar analysis to that described in (B) for the *DUSP6* gene. 516


Figure 6 A) Human CD34+ cells were isolated from human umbilical cord blood by FACS and transfected with either siRNA control or siRNA *MYB* and after 24 hours FAM+ cells were plated in complete methylcellulose and assayed for their ability to undergo full myeloid differentiation after 10 days in culture. B) Cells were also collected at 24 hours for the preparation and analysis of RNA expression. The histograms illustrate quantitative RT-PCR measurements of RNA expression for the *MYB*, *SPRY2*, *DUSP3*, *DUSP6*, *IL3RA* and *CSF1R* genes ** $p \le 0.001$,**** $p \le 0.0001$.

Figure 7 A) $MYB^{WT/WT}$ K11bL cells were transduced with shRNA SPRY2 and a corresponding shRNA control and 24 hours later were sorted on the basis of GFP 526 expression and plated in complete methylcellulose. After 7 days in culture colonies were 527 counted and their size scored GM: granulocyte / macrophage, G: Granulocyte, M: Macrophage, Mixed: containing all types. (N=3). B) MYB^{WT/WT} K11bL cells were transduced 528 with shRNA SPRY2 and transplanted into lethally irradiated recipients. Peripheral blood was 529 sampled monthly and the ratio of test donor to reference cells was determined. C) 530 Overexpression of SPRY2 in MYB^{KD/KD} K11bL cells followed by plating in complete 531 methylcellulose (*p≤0.05) showing both colony number and myeloid differentiation potential 532 in control and SPRY2 over expressing MYB^{KD/KD} K11bL cells. 533

Figure 8 Working model of pathway utilization in $MYB^{WT/WT}$ and $MYB^{KD/KD}$ K11bL cells. Schematic representation of IL-3 receptor signaling in K11bL cells, illustrating the differences in rpS6 phosphorylation observed in $MYB^{WT/WT}$ versus $MYB^{KD/KD}$ cells and how this appears to relate to changes in the signaling pathways utilized and the MYB-regulated signaling modulator SPRY2. The thickness of the arrows and the representation of the rpS6 phosphorylation sites gives a relative indication of the extent of pathway involvement and how this differs between the $MYB^{WT/WT}$ and $MYB^{KD/KD}$ cells.

541





В


MYB^{WT/WT}


→ Gr1


→ CD43


74

MYB^{KD/KD}















Figure 2







С

Α













Figure 4




























Enhanced cell proliferation, cell size and survival